New clinical data presented this week at the German Center for Infection Research (DZIF) Annual Meeting in Bonn highlight the potential of exhaled breath aerosol sampling as a practical alternative for respiratory pathogen detection in adults with cystic fibrosis.
The study, led by the team at Heidelberg University Hospital in collaboration with Avelo AG, evaluated the use of the AveloMask kit for PCR-based detection of Pseudomonas aeruginosa, a key pathogen in cystic fibrosis lung disease.
Beyond analytical performance, the study also underlined the usability of the method. Most participants found AveloMask easy to use, and it was generally preferred over sputum collection. This is especially relevant for patients who are unable or unwilling to produce sputum, where a patient-friendly alternative could improve access to microbiological testing.
These findings represent another encouraging step toward more accessible, non-invasive respiratory sampling. While larger studies are still needed, the results support the promise of AveloMask as a feasible tool to complement existing diagnostic pathways in cystic fibrosis care.
A sincere thank you to the team at Heidelberg University Hospital for this important work.
